[18F]FDG PET/CT不一致病灶总体积作为胃肠胰神经内分泌肿瘤患者的生物标志物:一项多中心研究
该多中心回顾性研究纳入44例晚期胃肠胰神经内分泌肿瘤患者,基于配对[18F]FDG与[68Ga]Ga-DOTATATE PET/CT识别不一致病灶并以[18F]FDG SUV 4为界勾画,发现不一致病灶总体积低者总生存较长(23.8个月 vs 9.4个月,HR 0.466,P=0.0221),肝内不一致病灶≤2个者生存也较长(31.8个月 vs 10.2个月,HR 0.389,P=0.0049)。
要点
- 低不一致病灶总体积组中位生存23.8个月,高于高总体积组的9.4个月(HR 0.466,P=0.0221)。
- 肝内不一致病灶≤2个者中位生存31.8个月,多于≥2个者的10.2个月(HR 0.389,P=0.0049)。
- 不一致病灶总体积可能是晚期胃肠胰神经内分泌肿瘤的预后生物标志物。
核心结论
- 不一致病灶总体积是胃肠胰神经内分泌肿瘤的潜在预后生物标志物,应在未来的神经内分泌肿瘤试验中进一步研究。
研究设计与样本
- 多中心回顾性研究,纳入44例晚期胃肠胰神经内分泌肿瘤患者,配对[18F]FDG与[68Ga]Ga-DOTATATE PET/CT间隔不超过85天。
- 以NETPET评分识别不一致病灶,并以[18F]FDG SUV 4为固定阈值勾画不一致病灶。
- 主要变量为不一致病灶总体积(TDV),按中位值将患者分为高TDV组和低TDV组;主要终点为总生存。
主要发现
- 44例患者中男性50%,中位年龄60岁;原发癌位于胰腺45%、小肠23%、结肠20%、其他12%。
- 5%为1级、48%为2级、48%为3级(3级中24%高分化、67%低分化、10%分化未知)。
- 总体中位生存为14.1个月。
- 低TDV组总生存长于高TDV组(中位体积43.7 cm3;生存时间23.8个月 vs 9.4个月;HR 0.466,95%CI 0.229-0.948;P=0.0221)。
- 肝内不一致病灶不超过2个者生存长于2个或以上者(31.8个月 vs 10.2个月;HR 0.389,95%CI 0.194-0.779;P=0.0049)。
临床怎么用
- 原文未据此给出推荐,仅指出不一致病灶总体积是潜在预后生物标志物并应在未来试验中进一步研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
[18F]FDG PET/CT and [68Ga]Ga-DOTATATE PET/CT are both used to predict tumor biology in neuroendocrine neoplasms. Although the presence of discordant ([18F]FDG-avid/non-[68Ga]Ga-DOTATATE-avid) disease predicts poor prognosis, the significance of the volume of such discordant disease remains undetermined. The aim of this study is to investigate discordant tumor volume as a potential biomarker in patients with advanced gastroenteropancreatic neuroendocrine neoplasms (GEPNENs). Methods: A multicenter retrospective study in patients with advanced GEPNENs and paired [18F]FDG and [68Ga]Ga-DOTATATE PET/CT no more than 85 d apart was conducted. Patients with discordant disease were identified by the NETPET score, and discordant lesions were contoured with a flat [18F]FDG SUV cutoff of 4. The primary variable of interest was the total discordant volume (TDV), which was the sum of the volumes of discordant lesions. Patients were dichotomized into high- and low-TDV cohorts by the median value. The primary endpoint was overall survival. Results: In total, 44 patients were included (50% men; median age, 60 y), with primary cancers in the pancreas (45%), small bowel (23%), colon (20%), and other (12%). Of the patients, 5% had grade 1 disease, 48% had grade 2 disease, and 48% had grade 3 disease (24% well differentiated, 67% poorly differentiated, 10% unknown within the grade 3 cohort). The overall median survival was 14.1 mo. Overall survival was longer in the low-TDV cohort than in the high-TDV cohort (median volume, 43.7 cm3; survival time, 23.8 mo vs. 9.4 mo; hazard ratio, 0.466 [95% CI, 0.229-0.948]; P = 0.0221). Patients with no more than 2 discordant intrahepatic lesions survived longer than those with 2 or more lesions (31.8 mo vs. 10.2 mo, respectively; hazard ratio, 0.389 [95% CI, 0.194-0.779]; P = 0.0049). Conclusion: TDV is a potential prognostic biomarker in GEPNENs and should be investigated in future neuroendocrine neoplasm trials.
引用
- Chan DL, Hayes AR, Karfis I, et al. [18F]FDG PET/CT-Avid Discordant Volume as a Biomarker in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Study. J Nucl Med. 2024. PMID: 38164579. doi:10.2967/jnumed.123.266346
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。